Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Check Point Software Technologies Expects 'Measured' Recovery Into 2027, Wedbush Says

Check Point Software Technologies Expects 'Measured' Recovery Into 2027, Wedbush Says

MT newswireMT newswire2026/11/03 14:55
10:55 AM EST, 11/03/2026 (MT Newswires) -- Check Point Software Technologies (CHKP) expects a "measured" recovery into 2027 after reporting Q3 results that largely met expectations, Wedbush said in a Tuesday note. Wedbush said Check Point's lower guidance reflects a difficult backdrop for its firewall business, higher memory prices, and more investment with changes to its go-to-market strategy. "While management highlighted this quarter as the trough in its growth, we wait on the sidelines to see this rebound materialize on its financials into FY27," the firm said. The company flagged multiple cost headwinds next year, including up to $50 million in incremental foreign exchange costs, a full year of sales hiring, and elevated artificial intelligence research and development investments, Wedbush said. The firm maintained a neutral rating on the stock, but increased its price target to $144 from $135. Price: 139.86, Change: -1.64, Percent Change: -1.16
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny